VivoVist(TM), 25 separate injection vials each containing 0.25 mL, 300 mg/mL

Artikelname:	VivoVist(TM), 25 separate injection vials each containing 0.25 mL, 300 mg/mL
Artikelnummer:	NNP-1301-25X0.25ML
Hersteller Artikelnummer:	1301-25X0.25ML
Alternativnummer:	NNP-1301-25X0.25ML
Hersteller:	Nanoprobes
Kategorie:	Sonstiges

VivoVist™ is a revolutionary new X-ray contrast agent from Nanoprobes. It enables higher contrast than competing agents, at a lower price that makes imaging in rats or other larger animals affordable for the first time.

VivoVist™ is a revolutionary nanotechnology super contrast agent of alkaline earth metal nanoparticles. VivoVist™ enables greatly enhanced X-ray imaging of blood vessels, tumors, and other tissues and organs. It is particularly useful for in vivo live animal microCT imaging, for studies of tumors, stroke, atherosclerosis and other vascular conditions, organ function, and other biological structural and functional analyses.

Features and Advantages

VivoVist™ provides approximately 3-4 times higher contrast than competing commercial microCT contrast agents. An Initial blood concentration of 50 mg/mL (5%), or 1 g/kg body weight (one-third of one vial for a 25 g mouse) gives greater than 3500 HU (Hounsfeld Units) contrast.
Long blood half-life of 14 hrs. VivoVist™ stays in the circulatory system longer than competing products. This enables extended imaging times and data collection, and allows longer diffusion into tumors and other features of interest, increasing their contrast.
Lowest price - makes imaging rats and larger animals affordable. VivoVist™ is more concentrated that competing products, meaning that fewer units are required to image larger animals. Less than two vials will provide good contrast in a 250 g rat.
Low toxicity (4 g/kg is well-tolerated). VivoVist™ can be administered in higher doses than competing products, to produce super-high contrst in fine structures or to accelerate loading of tumors or other features of interest.
Low osmolality, even at high concentrations. This means that injecting VivoVist™ will not greatly change the levels of electrolytes in the circulatory system. Impacts to metabolism, signaling and other processes that depend on maintaining a steady ionic strength are minimized.
Low viscosity: easy to inject into small mouse tail vein blood vessels (typical injection volume 0.25 mL). VivoVist™ is more easily injected, causes less injection site trauma to the animal, and may be administered more quickly and in higher concentration that more viscous contrast agents such as iodine-based reagents.
Can be imaged using MicroCT, clinical CT, planar X-ray, or mammography units. VivoVist™ is adaptable for any commonly used computed tomography system, giving users the flexibility to image in any desired instrument configuration.
Enhances radiotherapy X-ray dose to tumors and other targets. Because it absorbs X-rays so strongly, VivoVist™ increases the local X-ray dose. If it is concentrated in tumors or other therapeutic targets, it can provide a method for enhancing radiotherapy and increasing the efficacy of cancer therapy.

	Live mouse's head following intravenous delivery of VivoVist™ (250 ul). imaged with a Bruker SkyScan1276 at 13 um voxels resolution. The 3D image was generated and analyzed with Horos v4.0.0 software. Brain vessels of 50 microns or smaller were resolvable. Image kindly provided by Dr. Sean Marrelli, Department of Neurology in the McGovern Medical School at UTHealth (Houston, TX).
	MicroCT images of live mouse kidneys taken after one-vial IV injection of VivoVist™ . Dual use: 14hr blood half-life for vascular imaging and some able to enter glomerular filtration to follow excretion and kidney function in real time.
	Live mouse microCT imaging with VivoVist™
	Live mouse's head region imaged 5 days after intravenous delivery of VivoVist™ (150 ul = 45 mg Ba). An orthotopic MOC2 buccal tumor is contrasted by photon-counting microCT using spectral elemental decomposition. Image kindly provided by Dr. Cristian Badea, Duke University Medical Center. ("Enhancing In Vivo Preclinical Studies with VivoVist™ and Photon-Counting Micro-CT Imaging" https://doi.org/10.1117/12.3005892)
	Subcutaneous tumor (arrow) imaged by microCT 24 hrs after injection of 250 ul (75 mg Ba) VivoVist. Notice that tumor contrast is greater than bone contrast in regions and is not uniform showing variable EPR. Image kindly provided by Dr. Henry Smilowitz, University of Connecticut Health Center.
	Subcutaneous tumor growing in mouse imaged by microCT 24 hours after an intravenous injection of a vial of VivoVist. Note how variable the uptake is, putatively reporting on the extent of angiogenesis. Also note the high contrast and clear distinction from surrounding normal tissues.